Lyra Therapeutics is a clinical-stage biotechnology company that is developing novel treatments for ear, nose, and throat (ENT) diseases. The company was founded in 2015 and is based in Lexington, Massachusetts. Lyra's lead product candidate, LYR-210, is a drug-device combination that is designed to treat chronic rhinosinusitis (CRS), a common ENT condition. The company has received funding from several investors, including Polaris Partners, Perceptive Advisors, and RA Capital Management.